Heron Therapeutics, Inc. reported Q3 2025 Net Revenue of $38.2 million and year-to-date revenue of $114.3 million, with reaffirmed 2025 Net Revenue Guidance of $153 million – $163 million and adjusted EBITDA of $9.0 – $13.0 million. ZYNRELEF® Net Revenue grew 49% in Q3 2025 compared to Q3 2024, while APONVIE® Net Revenue grew 173% in the same period, supported by key initiatives. The company’s Acute Care franchise showed significant revenue growth, and ZYNRELEF® and APONVIE® updates reflect positive momentum and adoption. Oncology updates show consistent revenue growth. The company’s cash, cash equivalents, and short-term investments were $55.5 million as of September 30, 2025.

Heron Therapeutics, Inc. also announced the launch of new initiatives in Q3 2025 that are positively impacting commercial execution and driving demand for products. Financial guidance for 2025 includes Net Revenue of $153.0 – $163.0 million and Adjusted EBITDA of $9.0 – $13.0 million. The company’s focus on ZYNRELEF and APONVIE, along with steady growth in its Acute Care franchise, contributed to strong revenue performance in Q3 2025. The company is well-positioned for continued success in the coming quarters.

ZYNRELEF® for Postoperative Pain is the first extended-release dual-acting local anesthetic, delivering a fixed-dose combination of bupivacaine and meloxicam. ZYNRELEF has shown significantly reduced pain and increased patient comfort post-surgery compared to traditional methods. APONVIE® for Prevention of Postoperative Nausea and Vomiting is a substance P/neurokinin 1 (NK1) Receptor Antagonist. CINVANTI® for Chemotherapy Induced Nausea and Vomiting Prevention and SUSTOL® for CINV Prevention offer innovative solutions for patient care. Heron Therapeutics, Inc. focuses on improving patient lives through therapeutic innovations.

Read more at GlobeNewswire: Heron Therapeutics Announces Q3 2025 Financial Results and